Tobacco Use Disorder encompasses dependence on all forms of tobacco and nicotine delivery systems. 
 

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) defines Tobacco Use Disorder as a problematic pattern of tobacco or nicotine use leading to clinically significant impairment or distress.
 

A diagnosis is made when an individual meets at least 2 of the following 11 criteria within a 12-month period:
 

1. Larger Amounts / Longer Duration: Tobacco/nicotine is often taken in larger amounts or over a longer period than was intended.

2. Unsuccessful Efforts to Cut Down: There is a persistent desire or unsuccessful efforts to cut down or control tobacco/nicotine use.

3. Excessive Time Spent: A great deal of time is spent in activities necessary to obtain or use tobacco/nicotine.

4. Craving: Strong desire, urge, or craving to use tobacco/nicotine.

5. Role Failure: Recurrent tobacco/nicotine use resulting in a failure to fulfill major role obligations at work, school, or home.

6. Social / Interpersonal Problems: Continued tobacco/nicotine use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of use.

7. Activities Given Up: Important social, occupational, or recreational activities are given up or reduced because of tobacco/nicotine use.

8. Physical Hazards: Recurrent tobacco/nicotine use in situations in which it is physically hazardous (e.g., vaping in bed, smoking near flammable liquids).

9. Physical / Psychological Harm: Tobacco/nicotine use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by tobacco/nicotine.

10. Tolerance: A need for markedly increased amounts of tobacco/nicotine to achieve the desired effect, or a markedly diminished effect with continued use of the same amount.

11. Withdrawal: Manifestation of nicotine withdrawal symptoms (e.g., irritability, anxiety, difficulty concentrating, increased appetite, sleep disruption) or taking tobacco/nicotine to relieve or avoid withdrawal symptoms.

Diagnostic Severity Grading

• Mild: Presence of 2 to 3 criteria.

• Moderate: Presence of 4 to 5 criteria.

• Severe: Presence of 6 or more criteria.
   

Health Risks
 

1. Combustible Tobacco (Cigarettes, Cigars, Pipes)
 

• Cardiovascular: High risk for coronary artery disease, myocardial infarction, stroke, hypertension, and peripheral artery disease.

• Respiratory: Primary driver of COPD, chronic bronchitis, emphysema, and lung cancer.

• Oral & Mucosal: Periodontal disease, leukoplakia, and oral cancers.

• Oncology: High overall risk (lung, larynx, bladder, cervix, kidney, pancreas, acute myeloid leukemia).

2. Vaping & E-Cigarettes (ENDS)
 

• Cardiovascular: Endothelial dysfunction, microvascular damage, and elevated blood pressure/heart rate.

• Respiratory: Airway reactivity, asthma exacerbations, bronchitis, and EVALI (E-cigarette or Vaping Use-Associated Lung Injury) risk.

• Oral & Mucosal: Stomatitis, dry mouth, and altered oral microbiome.

• Oncology: Lower carcinogen burden relative to combustible smoke, but long-term data is limited.

3. Smokeless Tobacco & Nicotine Pouches (Snus, Dip, Zyn)
 

• Cardiovascular: Sympathetic arousal, elevated heart rate and blood pressure, and increased cardiac mortality.

• Respiratory: Minimal direct pulmonary exposure.

• Oral & Mucosal: Severe gingival recession, periodontal bone loss, and oral/esophageal leukoplakia.

• Oncology: Elevated risk for oral, esophageal, and pancreatic cancers.

Management
 

Patient education and behavioral support are essential first-line strategies for managing Tobacco Use Disorder. These methods help patients understand the necessity for quitting and help them to identify personal triggers, adjust daily routines, set a quit plan, improve their environment, and build skills to handle stress without nicotine. This stands as the sole primary first-line intervention for pregnant patients, adolescents, and light or intermittent smokers. To support this behavioral component, North Carolina residents have access to QuitlineNC, a free 24/7 state-funded resource offering evidence-based 1-on-1 coaching via phone, web chat, or text. Eligible participants can also receive a free supply of nicotine replacement therapy (NRT)—such as patches, gum, or lozenges—delivered directly to their home.

                                                              Medications

1. Nicotine Replacement Therapy (NRT)
 

NRT provides a clean, controlled dose of nicotine without harmful tars, carbon monoxide, or heavy metal aerosols. This is not indicated for those with active or recent cardiovascular events—such as a heart attack in the last two weeks, severe unstable angina, or uncontrolled arrhythmias. Caution and is also advised for patients with uncontrolled hypertension, active peptic ulcer disease, or severe renal or hepatic impairment.

​

• Nicotine Transdermal Patch (Over-the-Counter):

  • Mechanism: Long-acting baseline coverage delivering a slow, steady rate of nicotine through the skin over 16 to 24 hours.

  • Dosing Standard: Step-down dosing based on initial usage (e.g., 21 mg/day for heavy users; 14 mg/day for lighter users).

  • Side Effects: Local skin irritation (remove at bedtime if vivid dreams or sleep disturbances occur).
     

• Short-Acting NRTs (Over-the-Counter & Prescription):

  • Options: Nicotine gum, lozenge, nasal spray (Rx), and oral inhaler (Rx).

  • Mechanism: Fast-acting delivery designed to manage acute, breakthrough cravings.

  • Usage: Scheduled (every 1–2 hours) or as needed when cravings strike.

  • Combination NRT Strategy: The clinical gold standard is pairing a long-acting patch (for baseline suppression) with a short-acting option (gum/lozenge for breakthrough cravings).
     

2. Non-Nicotine Oral Medications (Prescription)
 

• Varenicline (Chantix):

  • Mechanism: Partial agonist at $\alpha_4\beta_2$ nicotinic acetylcholine receptors. It reduces cravings and withdrawal by stimulating low levels of dopamine release while blocking exogenous nicotine from binding if a slip-up occurs.

  • Efficacy: Considered the single most effective monotherapy for tobacco and nicotine cessation.

  • Dosing: Titrated over 1 week prior to a target quit date; standard course is 12 weeks.

  • Side Effects: Nausea (mitigated by taking with food and a full glass of water), vivid or abnormal dreams, insomnia, and headache.
     

• Bupropion SR (Zyban / Wellbutrin SR):

  • Mechanism: Norepinephrine-dopamine reuptake inhibitor (NDRI) that attenuates nicotine withdrawal symptoms and reduces cravings.

  • Benefits: Helps delay cessation-related weight gain; ideal for patients with comorbid depression.

  • Dosing: Titrated starting 1–2 weeks prior to target quit date.

  • Side Effects: Insomnia, dry mouth, agitation.

  • Major Safety Contraindications: Strictly contraindicated in patients with a history of seizure disorder, anorexia nervosa, bulimia, or those undergoing abrupt cessation of alcohol or sedatives.

Managing Withdrawal & Relapse Prevention
 

Nicotine withdrawal typically peaks within 24 to 48 hours of cessation and gradually subsides over 2 to 4 weeks. Key physical and psychological symptoms include:

• Intense cravings for nicotine

• Irritability, frustration, or anger

• Anxiety and restlessness

• Difficulty concentrating

• Increased appetite and weight gain

• Insomnia and sleep disruption

Behavioral Strategies for Success ("The 4 D's")
 

1. Delay: Wait 3–5 minutes when a craving hits; most acute cravings crest and decline within a few minutes.

2. Deep Breath: Practice slow, deep diaphragmatic breathing to calm the central nervous system.

3. Drink Water: Sip cold water to physically occupy the hands and mouth and flush the palate.

4. Distract: Engage in physical activity, shift environments, or contact a support person to redirect focus.